日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study

塔奎他单抗可改善复发或难治性多发性骨髓瘤患者的自述症状和健康相关生活质量：来自 1/2 期 MonumentTAL-1 研究的结果

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.35927
Schinke, Carolina; Touzeau, Cyrille; Oriol, Albert; Mateos, María-Victoria; Stevens, Don; Rasche, Leo; Qin, Xiang; Kato, Kelly; Bathija, Sacheeta; Katz, Eva G; Gries, Katharine S; Campagna, Michela; Masterson, Tara; Hilder, Brandi W; Tolbert, Jaszianne; Renaud, Thomas; Heuck, Christoph; Tomlinson, Chalmer; Moreau, Philippe; San-Miguel, Jesús; Rodríguez-Otero, Paula; Chari, Ajai
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

利用 Flatiron Health 数据库分析高危和非高危冒烟型多发性骨髓瘤患者的真实世界特征和预后

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-024-01170-z
Rajkumar, S Vincent; Mateos, María-Victoria; Schaeffer, Marcy; Lin, Xiwu; Bathija, Sacheeta; Gupta-Werner, Niodita; Lam, Annette; Carson, Robin; Dennis, Robyn; Kaila, Shuchita; Matt, Kathryn; Duran, Joana; Lonial, Sagar
多发性骨髓瘤
骨髓瘤
发表日期：2024
文献求助 收藏

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

捷克共和国单克隆丙种球蛋白病登记处的数据：冒烟型多发性骨髓瘤风险分层患者的临床特征和结局

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-023-00906-7
Sandecka, Viera; Popkova, Tereza; Stork, Martin; Maisnar, Vladimir; Minarik, Jiri; Jungova, Alexandra; Pavlicek, Petr; Stejskal, Lukas; Pospisilova, Lenka; Heindorfer, Adriana; Obernauerova, Jarmila; Gregora, Evzen; Sykora, Michal; Ullrychova, Jana; Wrobel, Marek; Kessler, Petr; Jelinek, Tomas; Kunovszki, Peter; Bathija, Sacheeta; Gros, Blanca; Wilbertz, Sabine; Cai, Qian; Lam, Annette; Spicka, Ivan
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

达雷妥尤单抗、泊马度胺和地塞米松与标准治疗方案在难治性复发/难治性多发性骨髓瘤患者中的间接治疗比较

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02226-x
He, Jianming; Berringer, Heather; Heeg, Bart; Ruan, Haoyao; Kampfenkel, Tobias; Dwarakanathan, Harikumaran R; Johnston, Stephen; Mendes, João; Lam, Annette; Bathija, Sacheeta; Mackay, Emma K
多发性骨髓瘤
骨髓瘤
发表日期：2022
文献求助 收藏